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Premature activation of the hypothalamic-pituitary-gonadal (HPG) axis manifests as gonadotropin-dependent precocious
puberty. The mechanisms behind HPG activation are complex and a clear etiology for early activation is often not elucidated.
Though collectively uncommon, the neoplastic and developmental causes of gonadotropin-dependent precocious puberty are very
important to consider, as a delay in diagnosis may lead to adverse patient outcomes. The intent of the current paper is to review
the neoplastic and developmental causes of gonadotropin-dependent precocious puberty. We discuss the common CNS lesions
and human chorionic gonadotropin-secreting tumors that cause sexual precocity, review the relationship between therapeutic
radiation and gonadotropin-dependent precocious puberty, and finally, provide an overview of the therapies available for height
preservation in this unique patient population.
1. Introduction
The onset of isosexual puberty is typically heralded by breast
development in girls and testicular enlargement in boys, usu-
ally followed by pubarche/adrenarche, the pubertal growth
spurt, and completion of secondary sexual development.
Traditionally, normal pubertal onset is considered to occur
between 8 and 13 years in girls and between 9 years 6 months
and 13 years 6 months in boys [1, 2]. Recent data suggests
that pubertal onset is occurring at earlier ages in girls,
especially among ethnic minorities and those with higher
body mass indices [3–10]. Therefore, it has been suggested to
redefine the age of precocious puberty in non-Hispanic black
girls to <6 years of age and to <7 years in all other girls [8].
It remains generally accepted that pubertal onset at less than
9 years remains precocious in boys. Significant controversy
has risen from these recommendations, given the possible
risk of delaying or missing the diagnosis of a pathologic
cause of precocious puberty [11, 12]. Importantly, sexual
development that occurs at a very young age or puberty that
progresses asynchronously or at an accelerated tempo may
indicate underlying pathology.
The prevalence of precocious puberty has been estimated
to be at least 10–20-fold higher in girls compared with
boys [13]. However, the likelihood of finding an organic
cause of precocious puberty is much higher in boys than
girls [13–16]. Neoplastic causes of precocious puberty are
uncommon but nonetheless important etiologies of preco-
cious sexual development, and prompt recognition of these
rare presentations is paramount.
The intent of the current manuscript is to review
the neoplastic and developmental causes of gonadotropin-
dependent precocious puberty and to share some of our
clinical experience at the Children’s Cancer Hospital of the
University of Texas M D Anderson Cancer Center. We will
not review gonadotropin-independent sexual precocity, such
as seen with sex steroid production by primary adrenal
or gonadal neoplasms. We will also discuss the potential
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eﬀects of radiation therapy for childhood tumors on the
hypothalamic-pituitary-gonadal (HPG) axis. Finally, we will
broadly review specific endocrine considerations regarding
the therapies available for height preservation in this unique
patient population.
2. Diagnosis of Gonadotropin-Dependent
Precocious Puberty
Gonadotropin-dependent precocious puberty results from
the premature activation of the HPG axis, which can
occur directly from tumor involvement of the hypotha-
lamus/pituitary or indirectly, such as seen with hydro-
cephalus (see below). The mechanisms that activate the HPG
axis are poorly understood, but recent developments have
contributed significantly to our understanding of pubertal
onset and subsequent reproductive health. Among the most
important recent discoveries has been the identification of
kisspeptin, a ligand for the G-protein coupled receptor 54
[17–19]. The gene encoding kisspeptin (Kiss1) has been
demonstrated to be mutated in some cases of hypogo-
nadotropic hypogonadism [20, 21] and to be upregulated
in some instances of precocious puberty [22–24]. It appears
that kisspeptin expression is in part regulated by androgens
and estrogens in a gender-specific manner [25]. Kisspeptin
expression also appears to be influenced by leptin [26], which
may help to explain the trend toward earlier pubertal onset
among overweight youth.
A careful history (including timing/extent of pubertal
changes, family history, and associated symptoms such as
headaches and visual loss) in addition to a comprehensive
physical examination (including past and current growth
velocity as well as a detailed assessment of sexual matu-
ration) are essential [27]. Gender-specific changes, such as
bilateral increase in testicular volume in boys and breast
development in girls, may suggest gonadotropin-dependent
pubertal development. However, it is important to realize
that these findings may be variable depending on etiology
and may also be found in gonadotropin-independent sexual
precocity [28, 29]. Chalumeau et al. has identified three
predictors of CNS lesions in girls, including age < 6 years,
estradiol > 100 pmol/L, and absence of pubic hair [12].
Distinguishing pubertal variants such as benign prema-
ture thelarche, adrenarche, and menarche from precocious
puberty is imperative so that significant pathology is not
missed.
A bone age (radiograph of the nondominant hand
and wrist) is vital in the evaluation of sexual precocity,
as it is expected to be advanced for chronologic age in
cases of pathologic precocious puberty [30]. Skeletal age
advancement in association with rapid progression of sexual
maturation defines sexual precocity, but determining the
exact etiology requires further evaluation.
The diagnosis of gonadotropin-dependent precocious
puberty is made by demonstrating a pubertal luteinizing
hormone (LH) at baseline (specifically LH/follicle stimu-
lating hormone (FSH) ratio > 0.2) [31] or in response to
gonadotropin-releasing hormone (GnRH) or GnRH analog
(GnRHa) stimulation [32–40]. The agent used, dosing, and
route of administration (intravenous or subcutaneous) vary
between studies, making it diﬃcult to set exact cutoﬀ values,
so these tests should always be interpreted in the clinical
context of the child being evaluated and the test being
performed.
At our center, our protocol is based upon that previ-
ously published by Garibaldi and colleagues [32], We draw
baseline LH, FSH, and testosterone/estradiol levels (gender-
dependent) followed by the subcutaneous administration
of 20 micrograms/kg of leuprolide acetate (concentration
of 1000mcg/0.2mL). LH and FSH samples are obtained
at 60, 120, and 180 minutes after injection with testos-
terone/estradiol repeated at 180 minutes after injection.
The use of ultrasensitive assays for measuring LH is of
utmost importance in interpreting the data [41, 42], but
the basal LH level may not always reflect pubertal stage
secondary to the cyclic changes in gonadotropin secretion
depending on pubertal status [43]. It has been reported
that GnRH-stimulated LH levels greater than 4.1 IU/L (using
ICMA) in boys and 3.3 IU/L (using ICMA) in girls are
suggestive of precocious puberty [42]. However, in girls,
there was significant overlap between prepubertal and puber-
tal values. Nevertheless, an LH-predominant response to
exogenous GnRH or GnRHa is anticipated in the child with
sexual precocity that is driven by premature activation of the
HPG axis.
If a pubertal LH level is demonstrated, brain magnetic
resonance imaging (MRI) is generally indicated to look for
a CNS lesion [44–46]. This is particularly true for very
young patients (age ≤ 6) who present with gonadotropin-
dependent precocious puberty and boys, noting that the rec-
ommendation for routine CNS imaging in older otherwise
asymptomatic girls remains controversial [46–49].
Tumors that overproduce human chorionic gonadotro-
pin (hCG) are also an important cause of precocious puberty
in boys due to the cross-reaction of hCG with the LH
receptor. Such tumors may be located centrally or periph-
erally (see further discussion below). Commonly, boys have
less pronounced testicular enlargement secondary to lack of
Sertoli cell stimulation from follicle stimulating hormone
(FSH). Of importance, baseline and stimulated LH levels
are prepubertal, but physical findings are consistent with
gonadotropin-dependent precocious puberty. Measurement
of serum β-hCG is the initial diagnostic test of choice, and
assessing β-hCG levels in both serum and cerebrospinal
fluid may help diﬀerentiate tumor location. In addition to
brain MRI to look for pinealomas or dysgerminomas, it
is also important to look for lesions in the mediastinum,
liver, and gonads. The work-up of an hCG-secreting tumor
should include a staged and symptom-oriented approach to
imaging of the brain, chest, liver, and gonads. Cyclic surges
and declines of β-hCG in such tumors have been described,
making repeat measurements often necessary in suspect
cases [50]. For the purposes of this review, such cases are
categorized as gonadotropin-dependent precocious puberty
because hCG is a gonadotropin and imparts a similar
clinical presentation to gonadotropin-dependent precocious
puberty.
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Table 1: Causes of gonadotropin-dependent precocious puberty.
(i) Idiopathic




(4) Germinomas (non-HCG secreting)
(5) Low-grade gliomas (juvenile pilocytic astrocytomas; optic pathway gliomas)
(iii) Paraneoplastic conditions (through the action of HCG on the LH receptor):




(d) Mediastinal (can occur in Klinefelter’s syndrome)
(2) Hepatoblastoma




(v) Postirradiation (through direct eﬀects on GnRH):
(1) Radiation therapy for childhood cancers (girls more susceptible)
(vi) Post-infectious, trauma, and bleed (through direct or indirect eﬀects on GnRH):
(1) Sometimes associated with arachnoid cyst development
GnRH, gonadotropin releasing hormone; HCG, human chorionic gonadotropin; LH, luteinizing
hormone.
3. Central Nervous System (CNS) Tumors
CNS tumors will be discussed in order of overall frequency of
occurrence in childhood. Though CNS tumors are relatively
common childhood neoplasms, tumors presenting with
precocious puberty are relatively uncommon [51]. A number
of CNS tumors contributing to precocious puberty have been
described. Commonly, these tumors are located in the sellar
and/or suprasellar region of the brain, thereby directly dis-
rupting the normal prepubertal inhibition of the HPG axis.
Sometimes tumors distant from the sella may indirectly cause
GnRH stimulation through pressure on the hypothalamic-
pituitary region from concurrent hydrocephalus [52]. Table 1
summarizes the potential causes of gonadotropin-dependent
precocious puberty.
Generally, CNS tumors are classified based on primary
morphology and tumor location in children. Symptoms and
signs of a primary CNS neoplasm depend on the growth rate
of the tumor, its location, and age of the child [53]. Clinical
findings can be quite varied, ranging from signs of increased
intracranial pressure (ICP) to localizing neurological signs
and symptoms. Weight loss, macrocephaly, and growth
failure may also suggest the presence of a CNS tumor [51].
Infratentorial tumors are located in the posterior fossa
and include medulloblastoma, cerebellar astrocytoma, brain
stem glioma, ependymoma, and atypical teratoid rhabdoid
tumors. These tumors commonly present with ataxia, cranial
neuropathies, and signs of increased ICP, such as headaches
and emesis. When precocious puberty presents in this
setting, it is most likely secondary to increased ICP causing
interference in the hypothalamic region.
Supratentorial tumors include suprasellar tumors such as
craniopharyngiomas, gliomas, germinomas, pineal tumors,
supratentorial primitive neuroectodermal tumors, and
ependymomas [53]. These tumors commonly present with
visual disturbances and signs of increased ICP as well as
possible neuroendocrine dysfunction.
3.1. Low-Grade Gliomas. Most low-grade gliomas (LGG)
in children are juvenile pilocytic astrocytomas (JPA) or
diﬀuse fibrillary astrocytomas, while oligodendrogliomas,
oligoastrocytomas, and mixed gliomas are much less com-
mon. JPAs are most often found in the cerebellar region,
though they may also be in other CNS regions including
the hypothalamus/optic pathway or the spinal cord. They
comprise approximately 50%–60% of CNS tumors, with
greater than 75% occurring during childhood [55]. The
average age of diagnosis is 6.5 to 9 years and boys are
more commonly aﬀected [56]. Though JPAs are generally
well circumscribed and slow growing, this indolent growth
pattern contributes significantly to their associated mor-
bidities. Metastases are uncommon, although tumors in the
hypothalamic and periventricular regions are more likely
to spread. Commonly, children with LGG present with
headache and seizure, though precocious puberty may be
among the initial manifestations (Figure 1).
LGGs associated with the optic pathway are commonly
found in patients with neurofibromatosis type 1 (NF-1).
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Figure 1: (a) A 3-year-old male presented with Tanner II pubic hair, testicular enlargement (∼6mL bilaterally), facial hair, and acne.
Laboratory evaluationwas consistent with gonadotropin-dependent sexual precocity. (b)MRI revealed a large suprasellarmass (arrows) with
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Figure 2: (a) A 3-year-old male with neurofibromatosis type 1 (note classic cafe´-au-lait macules) presented with a history of growth
acceleration and testicular enlargement. Bone age was advanced by 6 years. Gonadotropin-releasing hormone stimulation confirmed a
diagnosis of gonadotropin-dependent precocious puberty, with a peak luteinizing hormone level of 20.9mIU/mL. (b). MRI demonstrated a
large optic pathway glioma (asterisk). (Figures obtained with permission [54].)
While at least 15% of patients with NF-1 develop optic
pathway gliomas, approximately one-third of patients with
optic pathway gliomas are subsequently found to have NF-1
[53]. NF-1 aﬀects approximately one in 2500–3000 people
[57–59]. It is an autosomal dominant neurocutaneous
disorder with characteristic clinical findings, including cafe´-
au-lait macules with smooth borders (Figure 2), skinfold
freckling, cutaneous neurofibromas, and iris hamartomas
[60]. The clinical sequelae of NF-1 are due to inactivation
of the tumor suppressor gene neurofibromin-1, which in turn
normally inhibits the Ras gene, an important regulator of cell
growth, diﬀerentiation, and survival [61, 62]. Upregulated
Ras activity with or without a clear gene mutation may act
in part through activation of the mTOR pathway [63–65].
Optic gliomas in association with NF-1 seem to contribute
to precocious puberty through direct mass eﬀect (Figure 2).
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Figure 3: (a) A 10-year-old male presented with significant facial and pubic hair growth, deepening voice, and minimal testicular
enlargement (5mL bilaterally). Laboratory evaluation showed a markedly elevated β-hCG, pubertal testosterone, and suppressed
gonadotropin levels, consistent with hCG-mediated sexual precocity. (b) MRI revealed a large pineal mass (star). Note the eﬀects of tumor-
induced hydrocephalus on the hypothalamic-pituitary unit (arrows). Pathology revealed a mixed germ cell tumor and the patient had a
complete response to therapy. He entered endogenous puberty normally and has a final height of 68 inches (midparental height 71 inches).
The interested reader is referred to a recent comprehensive
review of NF1 by Williams et al. [66].
The diagnosis of LGGs is confirmed through biopsy
and histologic classification. Treatment of LGGs should
be individualized depending on the location and clinical
sequelae of the tumor, in addition to the overall clinical
context (i.e., whether or not the child has NF1). With
cerebellar JPAs, surgical resection is often curative. Generally,
even those with incomplete resection have excellent long-
term progression-free survival [53]. Chemotherapy is usually
recommended for symptomatic or progressive tumors with
the intention of delaying or avoiding radiotherapy. Further,
it is recommended that surgical resection be reserved only
for those with significant extension of the tumor, disfiguring
proptosis, and/or rapid clinical deterioration [67].
3.2. Ependymomas. Ependymomas tend to arise insidiously,
and despite their predilection towards the lateral posterior
fossa, they often cause obstructive hydrocephalus. Generally,
these tumors are slow growing and well circumscribed.
Ependymomas account for∼10% of CNS tumors in children
[68]. The mean age at diagnosis is 3 years, with 50% being
diagnosed prior to 5 years of age [69]. Boys are aﬀected
approximately 1.4 times more often than girls. Since greater
than 70% of ependymomas arise from the posterior fossa,
the signs at presentation are often a result of tumor-induced
hydrocephalus [69]. This obstructive hydrocephalus may in
turn lead to distinct eﬀects on the hypothalamic region
(Figure 3), including precocious pubertal onset.
For ependymomas, total resection is the optimal therapy,
which is more easily accomplished with supratentorial
ependymomas [69]. The role of adjunct radiotherapy in
children >3 years is well established, but it generally
is not considered in younger children secondary to the
potential eﬀects of radiation on the developing brain [70].
Furthermore, ependymomas appear to be fairly resistant
to chemotherapeutic regimens. However, there is renewed
interest in using local radiotherapy in children as young
as 1 year who have infratentorial tumors not amenable
to surgical removal [71]. One review of prognostic factors
shows that younger age appears to be the most important
factor influencing survival [72].
3.3. Pineal Tumors. Pineal tumors include germ cell tumors,
pineal parenchymal tumors, and glial tumors. These tumors
comprise as much as 7% of CNS tumors in childhood [73].
The pineal gland is located adjacent to the brain stem and
cerebral aqueduct, and tumors arising in this location may
cause obstructive hydrocephalus (Figure 3). Loss of upward
gaze (Parinaud’s syndrome) may be seen secondary to brain-
stem compression. Dissemination is found in approximately
25% of patients at time of diagnosis [73]. Precocious puberty
may occur with these tumors from either tumor-induced
hydrocephalus or through gonadotropin secretion in the case
of germ cell tumors (Figure 3; also see section on hCG-
secreting tumors) [74, 75].
With pineal tumors, biopsy and histologic classification
of tumor type is important prior to starting definitive ther-
apy, because radiologic appearance alone will not define the
type of pineal lesion present [73, 76]. The location of these
tumors makes complete surgical resection quite diﬃcult,
necessitating adjunctive radiotherapy and chemotherapy,
with variable long-term outcomes reported [53].
3.4. Craniopharyngioma. Craniopharyngiomas are slowly
growing tumors of the sellar region with insidious onset
[77, 78]. At the time of diagnosis, most patients have both
neurologic and endocrine signs and symptoms related to
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Figure 4: (a) A 4-year-old female presented with Tanner III-IV breast development and bone age advancement to 11 years of age. Leuprolide
stimulation (stimulated luteinizing hormone of 28mIu/mL) confirmed gonadotropin-dependent precocious puberty. (b) MRI revealed an
isointense mass (arrow) consistent with the diagnosis of a pedunculated hypothalamic hamartoma. This young girl’s puberty has been
adequately suppressed with depot leuprolide without further bone age advancement, pubertal development, neurologic sequelae, or mass
changes on serial MRIs.
disruption of hypothalamic-pituitary function and increased
ICP/mass eﬀect [77, 78]. These tumors account for 5% of
CNS tumors and the majority of sellar tumors diagnosed
in childhood [79]. They have a bimodal distribution with
peak incidences from 5–14 years and again from 65–74
years of age [78, 80–82]. While the endocrine manifestations
usually involve varying degrees of hypopituitarism, preco-
cious puberty may also occur [83, 84]. The growth spurt
typically expected with precocious puberty may be masked
by concomitant growth hormone deficiency [84]. Computed
tomography is helpful to identify the pathognomonic calci-
fication that is a radiologic hallmark of craniopharyngioma,
but MRI is preferred secondary to its superiority in detailing
anatomy and tumor extent [77, 78].
Total surgical resection of craniopharyngiomas is asso-
ciated with significant morbidity (including but not limited
to hypothalamic obesity, panhypopituitarism, and altered
neuropsychological profile) and mortality risk (up to 10%)
[85–87]. Recurrence, even with complete resection, occurs
in as many as 15% of these patients [78] and is associated
with an even higher morbidity and mortality risk [88, 89].
Selective debulking along with adjunctive radiotherapy may
be a more appropriate approach in these children [85].
4. Other Central Nervous System Lesions
4.1. Hypothalamic Hamartomas. Hypothalamic hamartomas
are nonneoplastic developmental lesions that are usually
histologically normal in appearance, but ectopic in posi-
tion [90]. They are composed of heterotopic grey matter,
neurons, and glial cells usually located at the base of the
third ventricle, near the tuber cinereum or mammillary
bodies. Hypothalamic hamartomas have a typical isointense
radiographic appearance on MRI (Figure 4). They are clas-
sified as pedunculated or sessile, depending on the width
of attachment to the tuber cinereum and their pattern
of growth, namely intra- or extraparenchymal [91, 92].
These lesions are believed to cause precocious puberty
(Figure 4) through endogenous pulsatile release of GnRH,
either independently or in concert with the GnRH-secreting
neurons of the hypothalamus [93]. It has also been suggested
that precocious puberty may be caused through the indirect
actions of glial factors, including transforming growth factor
alpha, that stimulate GnRH secretion from the hypothala-
mus [94, 95]. Removal of the hamartoma does not prevent
or inhibit further pubertal development in some patients. In
these patients, secondary activation of astroglial cells in the
surrounding hypothalamic tissue may cause increased GnRH
secretion, thereby inducing precocious puberty [94–96].
In patients with hamartomas, the classic triad of pre-
cocious puberty, developmental delay, and seizures, most
notably gelastic (“laughing”) seizures, is well described.
Patients with hypothalamic hamartoma usually present at
<4 years of age with precocious puberty [97, 98]. Precocious
puberty is found in 33%–85% of patients with a hypothala-
mic hamartoma, many of whom also develop seizures [99]. It
is a rare condition with a prevalence from 1 : 50,000–100,000
[100]. Pedunculated hamartomas are more likely to be
associated with precocious puberty while sessile hamartomas
are more likely to be associated with seizures [100, 101].
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Figure 5: A 4-year-old male with a history of asthma presented with complaints of pubertal changes (pubic hair growth, erections, sexual
behaviors, acne, deepening of the voice, accelerated linear growth, and increased muscle mass). (a) On examination, he had an enlarged
penis and Tanner III-IV pubic hair; testes were minimally enlarged (b) Bone age was 10 years and laboratory evaluation revealed a total
testosterone of 673 ng/dL (normal≤5), β-hCG of 22.9mIU/mL (normal≤1.0), and undetectable gonadotropin levels, consistent with hCG-
mediated sexual precocity. (c) CT chest revealed a 2.7×2.5 cm heterogeneous mass located in the anterior mediastinum (arrows). This lesion
was resected and confirmed to be a mature cystic teratoma. After surgery, the patient’s labs normalized, and he remains clinically prepubertal
at a chronological age of 9 years and bone age of 13 years.
Generally, the presentation ismore severe in younger patients
and tends to progress towards a debilitating seizure disorder
with marked developmental delay, while older patients tend
to have a less severe seizure disorder and less developmental
impairment.
Hypothalamic hamartomas are typically sporadic but
may also be associated with the Pallister Hall Syndrome
(PHS) [102]. PHS is an autosomal dominant syndrome with
anomalies including hypothalamic hamartoma, pituitary
abnormalities (including aplasia/dysplasia and/or hypopitu-
itarism), imperforate anus, and polydactyly [103, 104]. PHS
is due to mutations of the zinc-finger transcription factor
gene GLI3 on chromosome 7p13. GLI3 has been demon-
strated to have a role in sonic hedgehog-mediated brain
development. Disruption of this gene or associated genes
may explain some cases of hypothalamic hamartoma [105].
A number of other candidate genes are being investigated for
potential roles in hypothalamic hamartoma formation and
its clinical sequelae [106].
Treatment of hypothalamic hamartomas varies depend-
ing upon the patient’s symptoms and appearance of the
tumor. Generally, precocious puberty can be adequately
treated with GnRH analog therapy, whereas treating the
associated seizures can be much more challenging [107].
Te´llez-Zenteno et al. have recently reviewed the various
surgical and nonsurgical approaches to the treatment of
hypothalamic hamartomas [108]. The transcallosal surgical
approach has shown to be the most eﬀective for seizure
control, although a number of other therapies, including
stereotactic radiosurgery, have shown promise [108].
4.2. Arachnoid Cysts. Arachnoid cysts are relatively uncom-
mon intracranial lesions, usually developmental in origin,
but they may also develop after infection, trauma, or hem-
orrhage [109]. Furthermore, arachnoid cysts have also been
described in association with hypothalamic hamartomas and
tuberous sclerosis [110, 111]. Neurologic and visual field
disturbances are common. Arachnoid cysts are also com-
monly associated with other midline defects and optic nerve
hypoplasia [109]. When located in the suprasellar region,
endocrine findings are common, including gonadotropin-
dependent precocious puberty. A number of cases have
reported precocious puberty along with pituitary hormone
deficits as well as neurologic findings, specifically the bobble-
head doll phenomenon (rhythmic to-and-fro bobbling of the
head and trunk) [112–115]. Interestingly, delayed puberty
has also been reported with arachnoid cysts and other
suprasellar lesions [116, 117]. Arachnoid cysts can be
successfully managed with stereotactic ventriculocystostomy
[113, 118].
4.3. hCG-Producing Tumors. Germ cell tumors can produce
excessive hCG, which causes precocious puberty, almost
exclusively in males, via cross-reaction with the LH receptor.
Typically arising from the brain (Figure 3), mediastinum
(Figure 5), or gonads, these tumors are characterized based
on histologic diﬀerences. Regardless of locale, the child may
present with manifestations typical of isosexual precocious
puberty, but with suppressed basal and/or stimulated LH lev-
els. Girls with hCG-secreting tumors uncommonly present
with precocious puberty secondary to the requirement
for both LH and FSH eﬀects at the ovary for pubertal
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Figure 6: (a) Growth chart of a girl (solid circles) with a history of locally advanced retinoblastoma status post right eye enucleation,
chemotherapy, and radiotherapy (39.6Gy in 35 fractions) to the orbit, completed at the age of 17 months. Bone ages are represented by open
triangles. She was diagnosed with growth hormone (GH) deficiency and then gonadotropin-dependent sexual precocity and treated with
GH and depot leuprolide, respectively. The patient had menarche at age 8 and achieved a final height of 60 inches, well below mid-parental
height (MPH). (b) The patient’s identical twin sister (open circles) was already significantly taller by the age of 5 years. She had menarche at
age 12 and achieved a final adult height of 63.75 inches.
onset [119]. Intracranial hCG-secreting tumors may present
with isosexual precocious puberty, irrespective of gender,
secondary to disinhibition of GnRH, weak FSH eﬀect (as
a consequence of massive hCG secretion), and cosecretion
of estradiol by some dysgerminomas [120, 121]. There is
a well-recognized association of mediastinal hCG-secreting
germ cell tumors in patients with Klinefelter’s syndrome
[122, 123].
5. Radiation Related Precocious Puberty
Cranial irradiation is a commonly used modality for the
treatment of primary CNS tumors, and it can also be used
in the adjunctive treatment of other childhood malignancies.
The eﬀects of radiotherapy on the hypothalamic-pituitary
axis are variable and may evolve over a prolonged period
of time. Somatotrophs are the anterior pituitary cell type
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most sensitive to irradiation of the hypothalamic-pituitary
axis followed by the gonadotrophs, corticotrophs, and thy-
rotrophs [124].
Lower doses (18–24 Gray) of radiotherapy are often
associated with precocious puberty in girls [125–127],
whereas doses higher than 25 Gray can aﬀect both sexes,
with younger age at radiotherapy conferring a higher risk
of precocious puberty (Figure 6) [127–129]. Furthermore,
patients who develop precocious puberty following doses
of 30 Gray or more have a significant risk of ultimately
developing gonadotropin deficiency, while those who receive
doses in excess of 50 Gray are at increased risk of
delayed puberty (secondary to gonadotropin deficiency)
[130–132].
A recent report from the Childhood Cancer Survivor
Study found a significantly increased risk of both early and
late menarche in cancer survivors when compared with their
siblings [133]. In this study, radiotherapy >50 Gray and
age of treatment ≤4 years conferred a higher risk for early
menarche. While lower doses of radiotherapy also increased
the odds of early menarche, statistical significance was not
demonstrated. Another report of female acute lymphoblastic
leukemia (ALL) survivors demonstrated that those who were
treated with cranial radiotherapy had higher rates of early
menarche and those treated with craniospinal radiotherapy
had higher rates of both early and late menarche when
compared to those treated with chemotherapy alone [134].
This study also found an increased risk of early menarche
among those diagnosed at <5 years of age.
In childhood cancer survivors, the presentation of sexual
precocity can be subtle, the definitions of normal puberty
may not apply, and the diagnosis may not be straightforward.
For example, patients who develop precocious puberty after
irradiation may also have concomitant growth hormone
deficiency, which in turn can mask pubertal growth accelera-
tion and bone age advance, in turn delaying the diagnosis of
sexual precocity (Figure 6) [135, 136]. Importantly, testicular
volume in boys who are childhood cancer survivors may
not be reliable in the identification of pubertal onset,
and so a high index of suspicion and measurement of
gonadotropin and testosterone levels in boys previously





The appropriate treatment of gonadotropin-dependent pre-
cocious puberty is initially contingent on correctly identi-
fying the etiology. GnRHa therapy has been demonstrated
to be quite eﬀective at stalling puberty and preserving
adult height (particularly when started at <6 years of age)
in children with precocious puberty due to premature
activation of the HPG axis [139]. In children with hCG-
secreting tumors, the precocious puberty is best addressed
by treating the underlying tumor, although the natural
history of endogenous puberty in such children, who in
our experience tend to have markedly advanced skeletal
maturation, remains poorly characterized.
The treatment of brain lesions contributing to precocious
puberty is tumor dependent and is also dependent on a
number of other factors, including age, comorbidities, and
location of the tumor. Importantly, the endocrinologist
should carefully evaluate the remainder of the hypothalamic-
pituitary axis prior to definitive therapy and regularly
after therapy is complete [140]. Treatment of pituitary
hormone deficiencies should be undertaken as clinically indi-
cated, recognizing that the diagnosis of clinically important
endocrinopathies, such as central hypothyroidism, may be
diﬃcult to make in this population.
Children diagnosed with a brain tumor prior to 4 years of
age and those who receive radiation potentially aﬀecting the
hypothalamic-pituitary axis are at highest risk of adult short
stature [141]. Helping such children who develop sexual
precocity achieve a normal adult height may be diﬃcult, and
multimodality hormonal therapymay need to be considered.
Commonly, these children are not diagnosed until a later age
and/or may have such an advancement of skeletal maturity
that GnRHa therapy alone may not salvage adult height.
In these situations, the use of growth hormone and/or
aromatase inhibitor therapy may be considered but remains
largely unstudied in this population. The addition of growth
hormone to GnRHa therapy has shown variable responses
in height gain dependent on duration of therapy [142–144].
Among children who received spinal radiation therapy, age
at treatment appears to influence adult height most, and
boys seem to be less responsive to growth hormone therapy
than girls [145]. Aromatase inhibitors have been shown
to increase predicted adult height in normal boys treated
with growth hormone while allowing normal pubertal
progression [146–148]. Our initial clinical experience has
demonstrated an increased predicted adult height with the
use of growth hormone and/or aromatase inhibitors, but this
is an area that needs to be researched further via prospective
clinical trials in terms of long-term safety and eﬃcacy.
7. Conclusion
When evaluating children with precocious puberty, possible
neoplastic, developmental, and iatrogenic causes should
be considered in the diﬀerential diagnosis, particularly in
boys and in childhood cancer survivors. Through prompt
evaluation and treatment, long-term sequelae, specifically
short stature and possible impaired quality of life, may be
avoided. A heightened awareness of the neoplastic causes of
gonadotropin-dependent precocious puberty and vigilance
in the evaluation of children presenting with precocious
puberty are of utmost importance in order to avoid missing
important pathology.
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